JP2009536623A - 眼圧降下剤としてのアブノーマル・カンナビジオール化合物 - Google Patents

眼圧降下剤としてのアブノーマル・カンナビジオール化合物 Download PDF

Info

Publication number
JP2009536623A
JP2009536623A JP2009507924A JP2009507924A JP2009536623A JP 2009536623 A JP2009536623 A JP 2009536623A JP 2009507924 A JP2009507924 A JP 2009507924A JP 2009507924 A JP2009507924 A JP 2009507924A JP 2009536623 A JP2009536623 A JP 2009536623A
Authority
JP
Japan
Prior art keywords
group
alkyl
compound
hydrogen
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009507924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536623A5 (https=
Inventor
ジューン・チェン
ハンス・フリーリ
サイモン・ペティット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/409,868 external-priority patent/US7718830B2/en
Priority claimed from US11/409,871 external-priority patent/US7618966B2/en
Priority claimed from US11/409,570 external-priority patent/US7612101B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2009536623A publication Critical patent/JP2009536623A/ja
Publication of JP2009536623A5 publication Critical patent/JP2009536623A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009507924A 2006-04-24 2007-04-24 眼圧降下剤としてのアブノーマル・カンナビジオール化合物 Pending JP2009536623A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/409,868 US7718830B2 (en) 2006-04-24 2006-04-24 Abnormal cannabidiols as agents for lowering intraocular pressure
US11/409,871 US7618966B2 (en) 2006-04-24 2006-04-24 Abnormal Cannabidiols as agents for lowering intraocular pressure
US11/409,570 US7612101B2 (en) 2006-04-24 2006-04-24 Abnormal cannabidiols as agents for lowering intraocular pressure
PCT/US2007/067267 WO2007127711A2 (en) 2006-04-24 2007-04-24 Abnormal cannabidiols as agents for lowering intraocular pressure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013228274A Division JP2014058536A (ja) 2006-04-24 2013-11-01 眼圧降下剤としてのアブノーマル・カンナビジオール化合物

Publications (2)

Publication Number Publication Date
JP2009536623A true JP2009536623A (ja) 2009-10-15
JP2009536623A5 JP2009536623A5 (https=) 2010-06-17

Family

ID=38229040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009507924A Pending JP2009536623A (ja) 2006-04-24 2007-04-24 眼圧降下剤としてのアブノーマル・カンナビジオール化合物
JP2013228274A Pending JP2014058536A (ja) 2006-04-24 2013-11-01 眼圧降下剤としてのアブノーマル・カンナビジオール化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013228274A Pending JP2014058536A (ja) 2006-04-24 2013-11-01 眼圧降下剤としてのアブノーマル・カンナビジオール化合物

Country Status (7)

Country Link
US (2) US7968711B2 (https=)
EP (2) EP2010165A2 (https=)
JP (2) JP2009536623A (https=)
AU (1) AU2007244978B2 (https=)
BR (1) BRPI0710732A2 (https=)
CA (3) CA2648884C (https=)
WO (1) WO2007127711A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022540586A (ja) * 2019-07-12 2022-09-16 キャノピー グロウス コーポレイション カンナビノイド誘導体
JP2022547567A (ja) * 2019-09-09 2022-11-14 ケア ケミカル テクノロジーズ インコーポレイテッド カンナビノイド誘導体、前駆体、および使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282902A1 (en) * 2004-06-22 2005-12-22 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7618966B2 (en) * 2006-04-24 2009-11-17 Allergan, Inc. Abnormal Cannabidiols as agents for lowering intraocular pressure
US20120172339A1 (en) * 2009-07-10 2012-07-05 Northeastern University Angiogenic resorcinol derivatives
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
AU2023404746A1 (en) * 2022-12-02 2025-07-17 Benethera (Shaoxing) Biotechnology Co., Ltd. Compound and use thereof in treatment of treg-related diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0525167A (ja) * 1990-12-21 1993-02-02 Merck Sharp & Dohme Ltd 緑内障の治療に有用な置換ベンゼン誘導体
WO2006007227A2 (en) * 2004-06-22 2006-01-19 Allergan, Inc. Abnormal cannabidiols for lowering intraocular pressure

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL269094A (https=) * 1960-09-09
US3281424A (en) 1964-04-15 1966-10-25 Geigy Chem Corp Certain pyridobenzodiazepine derivatives
PL122834B1 (en) * 1977-09-13 1982-08-31 Process for preparing novel 3-/2-hydroxy-4-/substituted/-phenyl/-cyclohexanones
SE431085B (sv) * 1977-09-13 1984-01-16 Pfizer 3-(2-hydroxi-4-(substituerade)fenyl)cykloalkanoner och -cykloalkanoder och vissa derivat derav till anvendning for farmakologiska och medicinska endamal
US4529732A (en) * 1983-03-14 1985-07-16 Pfizer Inc. 2-[2-Hydroxy-4-(substituted)phenyl]piperidines
GB8329531D0 (en) 1983-11-04 1983-12-07 Ici America Inc Pyrazolopyridine cycloalkanones
YU134686A (en) 1985-07-30 1988-02-29 Nissan Chemical Ind Ltd Process for preparing new derivatives 3-(2h)-pyridazinone
GB8711525D0 (en) 1987-05-15 1987-06-17 Shell Int Research Oximino ether compounds
GB8722838D0 (en) 1987-09-29 1987-11-04 Shell Int Research Oximino ether compounds
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6828460B2 (en) * 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
NZ513452A (en) * 1999-03-22 2004-03-26 Pfizer Resorcinol derivatives
AU2001284362A1 (en) * 2000-09-21 2002-04-02 Pfizer Products Inc. Resorcinol derivatives
AU2002322466B2 (en) * 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
RS52392B (sr) * 2002-02-14 2013-02-28 Pharmacia Corporation Supstituisani piridinoni kao modulatori p38 map kinaze
US6863897B2 (en) * 2002-03-22 2005-03-08 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Stabilization of resorcinol derivatives in cosmetic compositions
WO2003091189A1 (en) 2002-04-25 2003-11-06 Virginia Commonwealth University Cannabinoids
EP1660421A2 (en) 2003-04-24 2006-05-31 Mallinckrodt Inc. Process for preparation of (+)-p-mentha-2,8-diene-1-ol
WO2005007632A1 (en) 2003-07-18 2005-01-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
US20050282902A1 (en) * 2004-06-22 2005-12-22 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US20050282913A1 (en) * 2004-06-22 2005-12-22 June Chen Abnormal cannabidiols as agents for lowering intraocular pressure
US20050282912A1 (en) * 2004-06-22 2005-12-22 June Chen Abnormal cannabidiols as neuroprotective agents for the eye
WO2007008548A2 (en) 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007014226A2 (en) * 2005-07-26 2007-02-01 The Board Of Trustees Of The University Of Illinois Compounds for the treatment of neurodegeneration and stroke
WO2008085972A2 (en) 2007-01-05 2008-07-17 Umagination Labs, L.P. Automatic cooking appliance shutoff apparatus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0525167A (ja) * 1990-12-21 1993-02-02 Merck Sharp & Dohme Ltd 緑内障の治療に有用な置換ベンゼン誘導体
WO2006007227A2 (en) * 2004-06-22 2006-01-19 Allergan, Inc. Abnormal cannabidiols for lowering intraocular pressure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YORIO T, EXPERT OPINION ON THERAPEUTIC PATENTS, vol. V14 N12, JPN5009008687, 2004, GB, pages 1743 - 1762, ISSN: 0002345575 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022540586A (ja) * 2019-07-12 2022-09-16 キャノピー グロウス コーポレイション カンナビノイド誘導体
JP2022547567A (ja) * 2019-09-09 2022-11-14 ケア ケミカル テクノロジーズ インコーポレイテッド カンナビノイド誘導体、前駆体、および使用
US12600707B2 (en) 2019-09-09 2026-04-14 Kare Chemical Technologies Inc. Cannabinoid derivatives, precursors and uses

Also Published As

Publication number Publication date
US7968711B2 (en) 2011-06-28
WO2007127711A2 (en) 2007-11-08
EP2123264A1 (en) 2009-11-25
AU2007244978B2 (en) 2013-05-30
CA2823724A1 (en) 2007-11-08
US20110269715A1 (en) 2011-11-03
CA2648884C (en) 2015-10-13
AU2007244978A1 (en) 2007-11-08
CA2648884A1 (en) 2007-11-08
EP2010165A2 (en) 2009-01-07
CA2823767A1 (en) 2007-11-08
BRPI0710732A2 (pt) 2011-11-08
WO2007127711A3 (en) 2008-03-27
JP2014058536A (ja) 2014-04-03
US20070249596A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
JP2014058536A (ja) 眼圧降下剤としてのアブノーマル・カンナビジオール化合物
DK2888239T3 (en) REDUCED CENTRAL CORCHET THICKENING USING HYDROFILE ESTER PRODUGS OF BETA-CHLORCYCLOPENTANE
US20050282902A1 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
US8420637B2 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
US7612101B2 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
ES2367920T3 (es) Beta-lactamas sustituidas y su uso en medicina.
US7718830B2 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
US8202855B2 (en) Substituted beta-lactams
DK3107906T3 (en) REDUCED CENTRAL CORNER MAP THICKNESS USING HYDROFILE ESTER PRODRUGS OF BETA-CHLORCYCLOPENTANE
CA2570853A1 (en) Abnormal cannabidiols for lowering intraocular pressure
US8541603B2 (en) Substituted cyclopentanes or cyclopentanones as therapeutic agents
AU2013205809A1 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
CN103764622A (zh) N,n-二烷基亚烷基酯、其组合物以及其使用方法
WO2011094225A1 (en) Therapeutically active cyclopentanes
HK1178524B (en) Therapeutic agents for treatment of ocular hypertension
HK1178524A (en) Therapeutic agents for treatment of ocular hypertension

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131101